Generic Drug Manufacturer SOHM, Inc. (SHMN) Building Regenerative Medicine Platform with LOI for Gene Editing Technology

• U.S.-based generic drug developer SOHM is working to build its product pipeline through registration for distribution in several states and the planned establishment of its own product manufacturing plant in Southern California
• SOHM is also focused on developing a regenerative medicine portfolio, having issued an LOI recently in its bid to acquire the gene editing technology ABBIE from CGA Intellectual Holdings Inc.
• ABBIE is a synthetic enzyme technology that includes a DNA binding solution and a DNA integration solution for introducing a functionally edited genome into an “enhanced” cell that could then be introduced into a patient’s body to repair the effects of cellular damage
• ABBIE is still in the early stages of development, but a principal aim of SOHM’s plans for the technology is to develop cells that can help repair damaged tissues in cardiac patients’ hearts 

Generic drug manufacturing and distributing innovator SOHM (OTC: SHMN) is an innovator in regenerative medicine, nutraceuticals and cosmeceuticals through the development of cost-effective generic drugs for the breadth of major treatment categories.

The company’s drive to sustain the pharmaceutical drug supply chain has led it to pursue the acquisition of a disruptive stem cell technology known as ABBIE for editing the genes of these select cells and then using the “enhanced” cells to treat conditions such as ischemic heart disease or heart failure.

SOHM signed a letter of intent in August to potentially acquire ABBIE (A Binding Based Integrating Enzyme) from CGA Intellectual Holdings Inc. (https://ibn.fm/Mf5w3). The company’s aim is to continue studying the optimal “payload” size for delivering the edited genes to the cells of interest in testing that uses animal and human cells outside of the body (ex vivo) for eventual “plug and play” purposes in vivo.

“The donor DNA can be customized to contain any gene or combination of genes. The investigator will leverage the ABBIE targeting system and guide payloads to sites of interest to change the state of the cell,” COO Dr. David Aguilar, Ph.D., stated in an August blog entry (https://ibn.fm/ANVvl). “By using ABBIE, researchers can insert genes that can enhance the properties or functions of a desired cell type. … ABBIE can be used to insert genes that can protect stem cells from oxidative stress, inflammation, or apoptosis and thereby increase therapeutic potential. In another example, ABBIE edited cells can restore function of dysfunctional organ tissue that was affected by a genetic disorder.”

SOHM hopes to establish that edited stem cells can be used to repair a damaged heart by transplanting the stem cells or their derivatives into the heart to either regenerate or replace the damaged tissue and restore its function. 

Stem cells have long been recognized as building blocks that have the ability to transform themselves into various types of cells in the body, making them an ideal target for editing and eventual insertion into damaged organs for corrective purposes.

“ABBIE is a novel and powerful technology designed to edit the genome of cells with high precision and efficiency,” Aguilar stated. “ABBIE will soon become a reality and make a difference in the lives of millions of people who suffer from heart disease.”

SOHM’s generic pharmaceutical, nutraceutical, cosmeceutical and OTC product pipeline is in the process of expansion as the company registers for distribution in a number of states. The company intends to have more than 25 SOHM labeled products in distribution by the end of the year or by early 2024.

SOHM also continues to work toward the launch of its own manufacturing facility in San Diego, Calif.

For more information, visit the company’s website at www.SOHM.com.

NOTE TO INVESTORS: The latest news and updates relating to SHMN are available in the company’s newsroom at https://ibn.fm/SHMN

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN